These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 480193)

  • 1. Investigation of the drug-binding defect in plasma from rats with glycerol-induced acute renal failure.
    Bowmer CJ; Lindup WE
    J Pharmacol Exp Ther; 1979 Sep; 210(3):440-5. PubMed ID: 480193
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Correction of protein binding defect in uremic sera by charcoal treatment.
    Craig WA; Evenson MA; Sarver KP; Wagnild JP
    J Lab Clin Med; 1976 Apr; 87(4):637-47. PubMed ID: 1270877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Decreased plasma protein binding of o-methyl red, methyl orange and phenytoin (diphenylhydantoin) in rats wtih acute renal failure [proceedings].
    Bowmer CJ; Lindup WE
    Br J Pharmacol; 1978 Jun; 63(2):367P. PubMed ID: 580898
    [No Abstract]   [Full Text] [Related]  

  • 4. Possible mechanisms for reduced plasma clearance of diflunisal in rat experimental renal failure.
    Lin JH; Ulm EH; Duggan DE
    J Pharmacol Exp Ther; 1986 Sep; 238(3):978-84. PubMed ID: 3746671
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reduced extraction of I-propranolol by perfused rat liver in the presence of uremic blood.
    Terao N; Shen DD
    J Pharmacol Exp Ther; 1985 May; 233(2):277-84. PubMed ID: 3999018
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased binding of drugs and dyes to plasma proteins from rats with acute renal failure: effects of ureter ligation and intramuscular injection of glycerol.
    Bowmer CJ; Lindup WE
    Br J Pharmacol; 1979 Jun; 66(2):275-81. PubMed ID: 465881
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Inability of accumulated metabolic byproducts of uremia to alter the extent of warfarin binding in charcoal treated plasma.
    Bachmann K; Conway P; Shapiro R
    Res Commun Chem Pathol Pharmacol; 1978 Apr; 20(1):117-30. PubMed ID: 663394
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prolonged impairment of the plasma-protein binding of phenytoin in the rat after a single dose of sodium oleate.
    Colburn WA; Gibaldi M
    Drug Metab Dispos; 1978; 6(4):452-5. PubMed ID: 28926
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of glycerol-induced acute renal failure on tissue glutathione and glutathione-dependent enzymes in the rat.
    Yeung JH
    Methods Find Exp Clin Pharmacol; 1991; 13(1):23-8. PubMed ID: 1870354
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of the binding characteristics of chlorophenoxyisobutyric acid to serum proteins in chronically uremic patients : influence of dialysis and heparine (author's transl)].
    Lacour B; Di Giulio S; Nicolaï A; Drüeke T; Debray M; Boulu RG
    Nephrologie; 1982; 3(1):19-22. PubMed ID: 7088259
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impaired plasma protein binding of phenytoin in uremia and displacement effect of salicylic acid.
    Odar-Cederlöf I; Borga O
    Clin Pharmacol Ther; 1976 Jul; 20(1):36-47. PubMed ID: 1277724
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Role of calcium in plasma protein binding and renal handling of alendronate in hypo- and hypercalcemic rats.
    Lin JH; Chen IW; deLuna FA; Hichens M
    J Pharmacol Exp Ther; 1993 Nov; 267(2):670-5. PubMed ID: 8246140
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Plasma protein binding and metabolic clearance of phenytoin in the rat.
    Colburn WA; Gibaldi M
    J Pharmacol Exp Ther; 1977 Dec; 203(3):500-6. PubMed ID: 925955
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Factors affecting serum protein binding of phenytoin, diazepam and propranolol in acute renal diseases.
    Tiula E; Haapanen EJ; Neuvonen PJ
    Int J Clin Pharmacol Ther Toxicol; 1987 Sep; 25(9):469-75. PubMed ID: 3679617
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma protein binding of zolpidem in liver and renal insufficiency.
    Pacifici GM; Viani A; Rizzo G; Carrai M; Ganansia J; Bianchetti G; Morselli PL
    Int J Clin Pharmacol Ther Toxicol; 1988 Sep; 26(9):439-43. PubMed ID: 3198298
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Plasma protein binding of phenytoin in health and disease: relevance to therapeutic drug monitoring.
    Perucca E
    Ther Drug Monit; 1980; 2(4):331-44. PubMed ID: 7013166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In-vitro study on the competitive binding of diflunisal and uraemic toxins to serum albumin and human plasma using a potentiometric ion-probe technique.
    Davilas A; Koupparis M; Macheras P; Valsami G
    J Pharm Pharmacol; 2006 Nov; 58(11):1467-74. PubMed ID: 17132209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cortisol binding in uremic plasma. II. Decreased cortisol binding to albumin.
    Rosman PM; Benn R; Kay M; Wallace EZ
    Nephron; 1984; 37(4):229-31. PubMed ID: 6462312
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.